(NHL). 2, 3 When recurrences occur after autologous BMT, treatment options are limited, and the prognosis is poor. 4 Allogeneic BMT is also an effective treatment for selecWe evaluated the response to and toxicity of allogeneic or autologous bone marrow transplantation (BMT) for ted categories of patients. for NHL at our institution. It is our practice to offer alloallogeneic bone marrow. Three patients are alive and geneic BMT mainly to patients who do not qualify for autodisease-free at 25, 22 and 7 months after allogeneic logous BMT due to refractory disease or extensive bone BMT. Four patients died of treatment-related causes marrow involvement. 8 Seventy-five patients had disease and one from disease recurrence. All four patients progression or recurrence after autologous BMT; 12 were undergoing autologous BMT had responsive relapses. treated with a second autologous (four patients) or alloThree patients received peripheral blood stem cells and geneic (eight patients) marrow or blood stem cell transone patient bone marrow. Two patients are alive and plant. disease-free at 12 and 30 months after autologous transAllogeneic BMT was offered to patients who had an plants. There were no treatment-related deaths; two HLA-compatible donor (HLA-identical sibling or 1 antigen patients died of disease recurrence. This retrospective mismatched relative), regardless of disease responsiveness. study shows that in selected patients, allogeneic or autoPatients who had chemosensitive recurrences, normocellulogous BMT is an effective salvage therapy for NHL lar marrows without involvement and who lacked an HLA which recurs after autologous BMT. compatible donor, were offered an autologous transplant. Keywords: lymphoma; relapse; BMT Additional eligibility criteria included a left ventricular ejection fraction у50%, adequate pulmonary function as measured by a diffusing capacity of carbon monoxide and Autologous BMT is an effective treatment for patients with a forced expiratory volume in 1 second у50% of the prechemotherapy sensitive recurrences of intermediate-grade dicted capacity, bilirubin р2 mg/dl, creatinine less than 1.5 lymphomas, 1 and is increasingly used for the initial treattimes normal and a performance status р1. ment of poor prognosis non-Hodgkin's lymphoma
Allogeneic BMT is also an effective treatment for selecWe evaluated the response to and toxicity of allogeneic or autologous bone marrow transplantation (BMT) for ted categories of patients. Allogeneic transplantation is associated with a lower risk of relapse than autologous patients with non-Hodgkin's lymphoma (NHL) who relapsed after autologous BMT. Since 1990, 172 patients transplantation, 5, 6 presumably because of graft-versuslymphoma (GVL) effects, or the lack of occult bone have received autologous BMTs for NHL at the MD Anderson Cancer Center and 75 have relapsed. Twelve marrow involvement. 7 For patients with recurrent NHL after autologous BMT, who had bone marrow involvement patients (median age, 42 years), with disease recurrence underwent either allogeneic BMT (eight patients) or a or inadequate marrow function, we offered allogeneic BMT. Patients with chemotherapy-sensitive relapse, no second autologous BMT (four patients). Ten patients received thiotepa, busulfan and cyclophosphamide as bone marrow involvement and good marrow function were offered a second autologous BMT. We report our results conditioning, one patient received cyclophosphamide and total body irradiation and one received BCNU, etowith these procedures in 12 patients. poside, Ara-c and melphalan. The median interval between the first and second transplants was 23.5 months (range 5-80 months). Three patients who Materials and methods underwent allogeneic BMT had refractory relapses, three had a responsive relapse and two were in complete Patients response (CR) at the time of BMT. Five patients Since 1990 , 172 patients have received autologous BMTs received peripheral blood stem cells and three patients, for NHL at our institution. It is our practice to offer alloallogeneic bone marrow. Three patients are alive and geneic BMT mainly to patients who do not qualify for autodisease-free at 25, 22 and 7 months after allogeneic logous BMT due to refractory disease or extensive bone BMT. Four patients died of treatment-related causes marrow involvement. 8 Seventy-five patients had disease and one from disease recurrence. All four patients progression or recurrence after autologous BMT; 12 were undergoing autologous BMT had responsive relapses.
treated with a second autologous (four patients) or alloThree patients received peripheral blood stem cells and geneic (eight patients) marrow or blood stem cell transone patient bone marrow. Two patients are alive and plant. disease-free at 12 and 30 months after autologous transAllogeneic BMT was offered to patients who had an plants. There were no treatment-related deaths; two HLA-compatible donor (HLA-identical sibling or 1 antigen patients died of disease recurrence. This retrospective mismatched relative), regardless of disease responsiveness. study shows that in selected patients, allogeneic or autoPatients who had chemosensitive recurrences, normocellulogous BMT is an effective salvage therapy for NHL lar marrows without involvement and who lacked an HLA which recurs after autologous BMT. compatible donor, were offered an autologous transplant. Keywords: lymphoma; relapse; BMT Additional eligibility criteria included a left ventricular ejection fraction у50%, adequate pulmonary function as measured by a diffusing capacity of carbon monoxide and Autologous BMT is an effective treatment for patients with a forced expiratory volume in 1 second у50% of the prechemotherapy sensitive recurrences of intermediate-grade dicted capacity, bilirubin р2 mg/dl, creatinine less than 1.5 lymphomas, 1 and is increasingly used for the initial treattimes normal and a performance status р1. ment of poor prognosis non-Hodgkin's lymphoma platinum (CVP) (two patients), mesna, ifosfamide, mitoxin three patients. tests; serology for HIV, cytomegalovirus, and hepatitis B and C. All relapses were histologically confirmed and the complete pre-transplant evaluation was repeated before the Second BMT: The conditioning regimen was chosen to be potentially non-cross-resistant to that used for the initial second transplant. Response to therapy was evaluated at 2 months, 4 months and every 3 months during the first year transplant. For patients who had received BCNU or TBIbased initial regimens, thiotepa (750 mg/m 2 ), busulfan (10 after the transplant, and annually thereafter.
Complete response was defined as the disappearance of mg/m 2 ) and cyclophosphamide (120 mg/kg) (TBC) were employed. An alternative chemotherapy regimen was used all measurable disease and absence of lymphoma-related FSCCL = follicular small cleaved cell lymphoma; CLL/SCLL = chronic lymphocytic leukemia/small cell lymphocytic lymphoma; LBL = lymphoblastic lymphoma; FDMCL = follicular and diffuse mixed cell lymphoma; DLCL = diffuse large cell lymphoma; Auto = autologous transplant; Allo = allogeneic transplant; RR = responsive relapse; RfR = refractory relapse; CR = complete remission; PR = partial response; CR 1 = first complete remission; BuCy = busulfan, cyclophosphamide; TBC = thiotepa, busulfan, cyclophosphamide; Cy = cyclophosphamide; E/VP = etoposide; TBI = total body irradiation; CARB = carboplatin; BEAC = BCNU, cyclophosphamide, etoposide and cytarabine; BEAM = BCNU, etoposide, Ara-C and melphalan; ICE = ifosfamide, carboplatin and etoposide; HLA-SIB = HLA-identical sibling; 1 Ag MM-Rel = 1 antigen mismatch-relative; PBSC = peripheral blood stem cells; BM = bone marrow; MTX = methotrexate; CSA = cyclosporine; MP = methylprednisolone; FK506 = tacrolimus. a Autologous transplant with marrow purged with anti-CD19 antibody.
symptoms for at least 1 month. Partial response (PR) was second transplant. Twenty-four patients relapsed in less than 6 months following the first transplant; 50% (12 defined as a reduction of more than 50% in the sum of the products of the two greatest perpendicular diameters of patients) had rapid disease progression and died during the first 6 months. Only one patient among the remaining 12 measurable lesions for more than 1 month. Primary resistant disease was defined as failure to achieve a PR after had a good performance status and an HLA identical sibling, and underwent a second transplant (allogeneic). front-line therapy. Refractory relapses (RfR) occurred when less than a PR was observed after the relapse, and for a Fifty-one patients relapsed more than 6 months after the first autologous transplant; 11 (21%) received a second responsive relapse (RR) at least a 50% reduction occurred.
Toxicity was scored according to the method of Bearman transplant (seven allogeneic and four autologous); two other patients are currently being prepared for allogeneic et al. 16 In this system, grade 1 toxicity is reversible without treatment, grade 2 is not life threatening, but requires treat-BMT. Thirty-eight patients did not undergo second BMT. In 16 patients (31%), BMT was not considered because ment. Grade 3 requires life-support intervention, and grade 4 is fatal. Regimen-related toxicity in each organ system of rapidly progressive disease, poor performance status or extensive bone marrow involvement in the absence of an was scored as the highest grade achieved in that organ system to day 28, except that deaths occurring after day 28 as HLA-compatible donor. Five patients (10%) had poor marrow function (two of them with myelodysplastic syndrome) a result of regimen-related toxicity occurring before day 28 were also scored as grade 4. Adverse events that could be and lacked an HLA-compatible donor. One patient refused an autologous BMT. Seven patients (14%) were considered attributed to infection (culture-documented), bleeding, or other medications were not scored as regimen-related toxby the attending physician to have 'indolent' relapse and a second transplant was not offered. Nine patients (17%) icity. The maximum toxicity was the highest grade recorded in any individual organ system and the cumulative toxicity were treated elsewhere at the time of relapse and second transplantation was not considered. score was the sum of the highest grades recorded for all eight organ systems.
Progression-free survival after the first transplant Statistical analysis
The median progression-free survival (PFS) after first BMT was 11.5 months and the median interval between first and Actuarial progression-free survival was calculated according to the method of Kaplan and Meier.
17 Two-tailed Studsecond BMT was 23.5 months. Only one patient underwent a second BMT within a year of initial BMT. ent's t-test was used for comparison of means.
Allogeneic transplants

Results
Patient characteristics: Five patients received allogeneic marrow and three peripheral blood progenitor cells. In Patient characteristics and the responses of their diseases to treatment are summarized in Tables 1 to 4. seven cases the donor was an HLA-identical sibling; in one a 1 antigen mismatched son. Three of the eight patients who underwent allogeneic BMT had disease that was Patient selection refractory to treatment and five had chemotherapy-sensitive disease. Four patients had bone marrow involvement and Patients with a progression-free survival after autologous BMT of less than 6 months were seldom considered for a two were in CR at the time of transplantation. Auto = autologous transplant; Allo = allogeneic transplant; CCR = continued complete response; GVHD = graft-versus-host disease; NA = not applicable; PFS = progression-free survival (months); GD = grade; CMV = cytomegalovirus; VOD = veno-occlusive disease.
Other abbreviations: see Table 1 . a Not assessed. Response, toxicity, survival, disease-free survival: Four of Autologous transplants six patients with active disease entered CR; one patient Patient characteristics: The four patients who underwent remained in CR and one patient transplanted in CR had autologous BMT had chemotherapy-sensitive disease at the disease progression. Two patients died at days +45 and +54 time of second BMT. Three patients were in CR at the time post-transplant and response was not evaluated. Three of transplantation. For the three patients who underwent patients are alive and progression free 750 days, 690 days stem cell transplantation, 9, 8 and 5 days of apheresis were and 220 days after BMT.
needed to collect the required number of progenitor cells. Treatment-related toxicities are shown in Table 5 . Severe toxicity (grades III or IV) occurred in three patients. Five
Response, disease-free survival and toxicity: Two patients patients died; one from disease progression, one from venocontinue in CR 13+ months and 31+ months after second occlusive disease of the liver and pneumonia, one from autologous BMT, two have relapsed 20 and 11 months after chronic GVHD and cytomegalovirus (CMV) pneumonia, second BMT and both have died. Grade 2 liver toxicity one from renal failure and sepsis and one from dissemiwas observed in one patient and grade 2 stomatitis in two nated aspergillus. Toxicity was more severe among patients patients. No episodes of bacteremia were documented and who had received TBI as part of the conditioning regimen no other severe toxicities occurred (Table 5) . for the first transplant (n = 4). Their mean toxicity score Engraftment: Neutrophil engraftment occurred in all was 10, compared to 5.5 for those that were not initially patients. The median time to reach an ANC у0.5 × 10 9 /l treated with TBI (P = 0.046, Student's t-test).
was 20 days (range 10-31). Graft failure occurred in one patient (ANC Ͻ 0.5 × x10 9 /l and platelet count Ͻ20 × 10 9 /l Engraftment and GVHD: Neutrophil engraftment occurred at day +30 post-transplant) and was treated successfully in all patients. The median time to achieve an ANC with GM-CSF and interleukin 3. Median time to achieve a у0.5 × 10 9 /l was 9.5 days (range 8-18). The median time platelet count у20 × 10 9 /l was 46 days (range 25-60). One to achieve a platelet count у20 × 10 9 /l for the three patients patient required infusion of bone marrow because of failure who continue to be in CR was 79 days (13, 79 and 95 days).
of PBSC to engraft. Grade II or III acute GVHD developed in seven patients. Five patients survived beyond 100 days after BMT and could be evaluated for chronic GVHD; fatal chronic GVHD Discussion developed in one; one currently has extensive GVHD of the gut, two are alive without GVHD and one patient died
The use of autologous BMT for lymphoma is increasing, and disease recurrence is the major cause of treatment failat day +123 without evidence of chronic GVHD. Table 5 Regimen-related toxicity, infections and treatment-related effect. 19, 20 It was therefore usually preferred if a compatible deaths related donor was available. The majority of patients in our series received condition- were poorly tolerated in these heavily pretreated patients.
Pulmonary
Autologous BMT was better tolerated, and no treatment- logous transplants for NHL (22 patients) and Hodgkin's disease (12 patients). In 20 cases the indication for second BMT was disease relapse. The 2-year survival rate was ure. There is no effective long-term therapy for these patients. The response rate to conventional chemotherapy 48% and the treatment-related death rate was 18%. In our study, the patients to whom repeat BMT was is low, and the majority of patients die of disease progression. 4 Such patients are also often ineligible for studies offered represented a selected group, who had prolonged remissions after their initial BMT. All received salvage of investigational new agents, mainly because they have limited hematopoietic reserve and have received extensive chemotherapy, being referred for the second transplant when good performance status and clinical stability were prior treatment.
We have explored the use of second transplantation utilachieved. These factors, allied to psychological and financial aspects of such prolonged treatment reflected on the izing alternative, non-crossresistant conditioning regimens. High-dose chemotherapy regimens generally involve median interval of 23.5 months between the first and second BMT. alkylating agents, among which crossresistance is unlikely. 18 It is therefore conceivable that for patients in The experience with second BMT in leukemia suggests that a longer interval between first and second BMT has a whom one high-dose regimen fails, an alternative regimen will be beneficial, especially if the patient's disease has significant influence on survival. Among 90 patients who underwent a second BMT for leukemia recurrence, the surmaintained some degree of chemotherapy sensitivity. Allogeneic marrow may offer additional advantages, such as the vival rate for patients with an interval between BMTs that was greater than 566 days was 36%, whereas it was 9% lack of tumor contamination, and a graft-versus-lymphoma second BMT is feasible in selected patients with NHL. plications but have the potential to promote durable
